How many clinical trials are tracked for gastrointestinal stromal tumor?

32 trials are tracked, 1 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

Log in / Sign up

Gastrointestinal stromal tumor

Part of Neoplasms, Connective Tissue

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for gastrointestinal stromal tumor

32 trials tracked for gastrointestinal stromal tumor: 8 in phase 3 or 4 and 1 with published results. The most-cited published study has 406 citations.

32Trials tracked

8Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 4 2 Phase 3 6 Phase 2 18 Phase 1 1 Other / NA 5

Phase 3 Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies Completed · 406 cited
Phase 4 Study for Patients Previously Treated in Avapritinib Clinical Trials Completed
Phase 4 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib Completed
Phase 3 Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. Completed
Phase 3 A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST) Completed
Phase 3 Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) Completed

Show 26 more trials

Phase 3 Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib Completed
Phase 3 Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT Completed
Phase 2 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed
Phase 2 Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib Completed
Phase 2 Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors Completed
Phase 2 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed
Phase 2 A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) Completed
Phase 2 Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors Completed
Phase 2 Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor Completed
Phase 2 CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors Completed
Phase 2 A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) Completed
Phase 2 Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment Completed
Phase 2 Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor Completed
Phase 2 Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 Completed
Phase 2 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed
Phase 2 A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Completed
Phase 2 Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation Completed
Phase 2 Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor Completed
Phase 2 The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). Completed
Phase 2 A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor Completed
Phase 1 Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST Completed
N/A Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle Completed
N/A Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). Completed
N/A Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene Completed
N/A Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo Completed
N/A A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

Questions about gastrointestinal stromal tumor

Are there specific genetic markers that make gastrointestinal stromal tumors more likely to return?

Yes, mutations in KIT and PDGFRA genes, as well as germline variants near SLC6A18 and TERT, are linked to higher recurrence risk in GIST.

Full answer →

What are the 5-year relapse-free survival results for high-risk GIST patients on adjuvant imatinib?

For high-risk GIST patients, 5-year relapse-free survival is about 74% with ≤3 years of adjuvant imatinib and 84% with >3 years, based on a 2026 retrospective study.

Full answer →